Status:
COMPLETED
Cross-sectional Study on Human Papillomavirus Type Distribution in Adult Women Diagnosed With Cervical Cancer
Lead Sponsor:
GlaxoSmithKline
Conditions:
Neoplasms, Uterine Cervix
Cervical Cancer
Eligibility:
FEMALE
21+ years
Brief Summary
The current study will elucidate the human papillomavirus type distribution in a population of women diagnosed with cervical high grade pre-cancerous lesions and invasive cervical cancer in Sri Lanka.
Eligibility Criteria
Inclusion
- A female \> 21 years of age at the time of diagnosis of invasive cervical cancer or cervical intraepithelial neoplasia - moderate or severe.
- Histologically confirmed diagnosis of cervix intraepithelial neoplasia - moderate or severe, invasive cervical cancer, glandular lesions and other epithelial tumours.
- Written informed consent obtained from the subject prior to study start.
- Subjects who the investigator believes can and will comply with the requirements of the protocol, should be enrolled in the study.
Exclusion
- Previous vaccination against human papillomavirus.
- History of chemotherapy or radiotherapy for cervical cancer.
- Subjects with recurrent episodes of invasive cervical cancer or cervical intraepithelial neoplasia- moderate or severe.
Key Trial Info
Start Date :
October 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01221987
Start Date
October 1 2009
End Date
September 1 2010
Last Update
April 30 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.